Zenas BioPharma Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqGS:ZBIO Recent Insider Transactions by Companies or Individuals
Date	Value	Name	Entity	Shares	Max Price
18 Feb 25	BuyUS$166,750	Leon Moulder	Individual	25,000	US$6.67
07 Feb 25	BuyUS$77,600	Tim Xiao	Individual	10,000	US$7.76
04 Dec 24	BuyUS$718,100	Leon Moulder	Individual	70,000	US$10.76
19 Nov 24	BuyUS$148,925	Leon Moulder	Individual	10,000	US$15.00

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of ZBIO?
Owner Type	Number of Shares	Ownership Percentage
Individual Insiders	366,736	0.825%
Private Companies	3,761,359	8.46%
Public Companies	4,513,161	10.1%
VC/PE Firms	12,397,192	27.9%
Institutions	23,439,945	52.7%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 25 shareholders own 101.15% of the company

Ownership	Name	Shares	Current Value	Change %	Portfolio %
11.7%	SR One Capital Management, LP	4,911,539	US$106.9m	0%	14.17%
11%	FMR LLC	4,644,279	US$101.1m	39.7%	0.01%
8.93%	Enavate Sciences	3,761,359	US$81.8m	0%	no data
7.36%	Xencor, Inc.	3,098,380	US$67.4m	0%	no data
6.49%	New Enterprise Associates, Inc.	2,733,719	US$59.5m	4.58%	2.98%
5.94%	Longitude Capital Management Co., LLC	2,501,934	US$54.4m	0%	9.87%
5.34%	Novo Holdings A/S	2,250,000	US$49.0m	1.58%	0.06%
4.49%	Fairmount Funds Management LLC	1,892,806	US$41.2m	0%	3.11%
4.42%	Federated Hermes, Inc.	1,861,838	US$40.5m	60.8%	0.08%
4.37%	NVP Associates, LLC	1,838,482	US$40.0m	0%	5.27%
3.97%	Tellus BioVentures, LLC	1,672,039	US$36.4m	0%	no data
3.71%	Deerfield Management Company, L.P.	1,562,942	US$34.0m	0%	0.53%
3.36%	Bristol-Myers Squibb Company	1,414,781	US$30.8m	0%	no data
2.81%	Vivo Capital, LLC	1,183,260	US$25.7m	0%	1.54%
2.6%	BlackRock, Inc.	1,095,609	US$23.8m	8.04%	no data
2.6%	ArrowMark Colorado Holdings, LLC	1,094,338	US$23.8m	-0.28%	0.42%
2.36%	The Vanguard Group, Inc.	992,212	US$21.6m	1.67%	no data
2.09%	Wellington Management Group LLP	878,918	US$19.1m	0.61%	no data
1.85%	Pivotal BioVenture Partners LLC	779,045	US$17.0m	5.76%	6.9%
1.52%	Rock Springs Capital Management LP	640,467	US$13.9m	-27.1%	0.71%
1.15%	T. Rowe Price Group, Inc.	485,202	US$10.6m	-6.26%	no data
0.89%	Geode Capital Management, LLC	373,617	US$8.1m	4.61%	no data
0.77%	Eversept Partners, L.P.	325,479	US$7.1m	-27%	0.6%
0.74%	State Street Global Advisors, Inc.	310,236	US$6.8m	16.5%	no data
0.7%	Citadel Advisors LLC	293,785	US$6.4m	0%	0.01%

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/10/05 04:23
End of Day Share Price	2025/10/03 00:00
Earnings	2025/06/30
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Zenas BioPharma, Inc. is covered by 8 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Yigal Nochomovitz	Citigroup Inc
Yatin Suneja	Guggenheim Securities, LLC
Matthew Caufield	H.C. Wainwright & Co.